3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Plasmacytoma
1
Nasopharyngeal Carcinoma
1
Meningeal Carcinomatosis
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Glioma
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Nivolumab
37
pembrolizumab
26
cabozantinib
26
Specimen Handling
23
Magnetic Resonance Spectroscopy
21
Ipilimumab
19
lenvatinib
13
belzutifan
13
Axitinib
13
CTLA-4 Antigen
10
Sunitinib
9
Radiosurgery
8
Biopsy
8
atezolizumab
7
fludarabine
4
avelumab
4
aldesleukin
4
Immunoglobulin G
4
Disulfides
4
zimberelimab
3
toripalimab
3
tivozanib
3
pazopanib
3
palbociclib
3
durvalumab
3
cemiplimab
3
Surveys and Questionnaires
3
Nephrectomy
3
Everolimus
3
Cyclophosphamide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Immunotherapy, Adoptive
×
90 days
×
Clear all
No trials found.